527 related articles for article (PubMed ID: 27084659)
1. Acute Toxicity and Quality of Life in Patients With Prostate Cancer Treated With Protons or Carbon Ions in a Prospective Randomized Phase II Study--The IPI Trial.
Habl G; Uhl M; Katayama S; Kessel KA; Hatiboglu G; Hadaschik B; Edler L; Tichy D; Ellerbrock M; Haberer T; Wolf MB; Schlemmer HP; Debus J; Herfarth K
Int J Radiat Oncol Biol Phys; 2016 May; 95(1):435-443. PubMed ID: 27084659
[TBL] [Abstract][Full Text] [Related]
2. Ion Prostate Irradiation (IPI) - a pilot study to establish the safety and feasibility of primary hypofractionated irradiation of the prostate with protons and carbon ions in a raster scan technique.
Habl G; Hatiboglu G; Edler L; Uhl M; Krause S; Roethke M; Schlemmer HP; Hadaschik B; Debus J; Herfarth K
BMC Cancer; 2014 Mar; 14():202. PubMed ID: 24641841
[TBL] [Abstract][Full Text] [Related]
3. Four-Year Outcomes From a Prospective Phase II Clinical Trial of Moderately Hypofractionated Proton Therapy for Localized Prostate Cancer.
Grewal AS; Schonewolf C; Min EJ; Chao HH; Both S; Lam S; Mazzoni S; Bekelman J; Christodouleas J; Vapiwala N
Int J Radiat Oncol Biol Phys; 2019 Nov; 105(4):713-722. PubMed ID: 31199994
[TBL] [Abstract][Full Text] [Related]
4. Five-Year Biochemical Results, Toxicity, and Patient-Reported Quality of Life After Delivery of Dose-Escalated Image Guided Proton Therapy for Prostate Cancer.
Bryant C; Smith TL; Henderson RH; Hoppe BS; Mendenhall WM; Nichols RC; Morris CG; Williams CR; Su Z; Li Z; Lee D; Mendenhall NP
Int J Radiat Oncol Biol Phys; 2016 May; 95(1):422-434. PubMed ID: 27084658
[TBL] [Abstract][Full Text] [Related]
5. Hypofractionated Radiation Therapy to the Prostate Bed With Intensity-Modulated Radiation Therapy (IMRT): A Phase 2 Trial.
Leite ETT; Ramos CCA; Ribeiro VAB; Salvajoli BP; Nahas WC; Salvajoli JV; Ynoe Moraes F
Int J Radiat Oncol Biol Phys; 2021 Apr; 109(5):1263-1270. PubMed ID: 33346091
[TBL] [Abstract][Full Text] [Related]
6. Hypofractionated Versus Standard Fractionated Proton-beam Therapy for Low-risk Prostate Cancer: Interim Results of a Randomized Trial PCG GU 002.
Vargas CE; Hartsell WF; Dunn M; Keole SR; Doh L; Eisenbeisz E; Larson GL
Am J Clin Oncol; 2018 Feb; 41(2):115-120. PubMed ID: 26523442
[TBL] [Abstract][Full Text] [Related]
7. Proton Therapy as Salvage Treatment for Local Relapse of Prostate Cancer Following Cryosurgery or High-Intensity Focused Ultrasound.
Holtzman AL; Hoppe BS; Letter HP; Bryant C; Nichols RC; Henderson RH; Mendenhall WM; Morris CG; Williams CR; Li Z; Mendenhall NP
Int J Radiat Oncol Biol Phys; 2016 May; 95(1):465-471. PubMed ID: 26883560
[TBL] [Abstract][Full Text] [Related]
8. SHARP hypofractionated stereotactic radiotherapy is well tolerated in prostate cancer : Toxicity and quality of life assessment.
Rucinska M; Kieszkowska-Grudny A; Nawrocki S
Strahlenther Onkol; 2016 Jul; 192(7):449-57. PubMed ID: 27221312
[TBL] [Abstract][Full Text] [Related]
9. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
[TBL] [Abstract][Full Text] [Related]
10. Moderately HRT vs. CRT for localized prostate cancer using image-guided VMAT with SIB: evaluation of acute and late toxicities.
Vassis S; Nöldeke B; Christiansen H; von Klot CA; Merten R
Strahlenther Onkol; 2020 Jul; 196(7):598-607. PubMed ID: 32040691
[TBL] [Abstract][Full Text] [Related]
11. Acute toxicity in high-risk prostate cancer patients treated with androgen suppression and hypofractionated intensity-modulated radiotherapy.
Pervez N; Small C; MacKenzie M; Yee D; Parliament M; Ghosh S; Mihai A; Amanie J; Murtha A; Field C; Murray D; Fallone G; Pearcey R
Int J Radiat Oncol Biol Phys; 2010 Jan; 76(1):57-64. PubMed ID: 19395192
[TBL] [Abstract][Full Text] [Related]
12. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer (HYPO-RT-PC): patient-reported quality-of-life outcomes of a randomised, controlled, non-inferiority, phase 3 trial.
Fransson P; Nilsson P; Gunnlaugsson A; Beckman L; Tavelin B; Norman D; Thellenberg-Karlsson C; Hoyer M; Lagerlund M; Kindblom J; Ginman C; Johansson B; Björnlinger K; Seke M; Agrup M; Zackrisson B; Kjellén E; Franzén L; Widmark A
Lancet Oncol; 2021 Feb; 22(2):235-245. PubMed ID: 33444529
[TBL] [Abstract][Full Text] [Related]
13. Prostate bed irradiation with alternative radio-oncological approaches (PAROS) - a prospective, multicenter and randomized phase III trial.
Koerber SA; Katayama S; Sander A; Jaekel C; Haefner MF; Debus J; Herfarth K
Radiat Oncol; 2019 Jul; 14(1):122. PubMed ID: 31291969
[TBL] [Abstract][Full Text] [Related]
14. Hypofractionated accelerated radiotherapy using concomitant intensity-modulated radiotherapy boost technique for localized high-risk prostate cancer: acute toxicity results.
Lim TS; Cheung PC; Loblaw DA; Morton G; Sixel KE; Pang G; Basran P; Zhang L; Tirona R; Szumacher E; Danjoux C; Choo R; Thomas G
Int J Radiat Oncol Biol Phys; 2008 Sep; 72(1):85-92. PubMed ID: 18355982
[TBL] [Abstract][Full Text] [Related]
15. Five-Year Outcomes of a Phase 1 Dose-Escalation Study Using Stereotactic Body Radiosurgery for Patients With Low-Risk and Intermediate-Risk Prostate Cancer.
Zelefsky MJ; Kollmeier M; McBride S; Varghese M; Mychalczak B; Gewanter R; Garg MK; Happersett L; Goldman DA; Pei I; Lin M; Zhang Z; Cox BW
Int J Radiat Oncol Biol Phys; 2019 May; 104(1):42-49. PubMed ID: 30611838
[TBL] [Abstract][Full Text] [Related]
16. Carbon ion radiotherapy in advanced hypofractionated regimens for prostate cancer: from 20 to 16 fractions.
Okada T; Tsuji H; Kamada T; Akakura K; Suzuki H; Shimazaki J; Tsujii H;
Int J Radiat Oncol Biol Phys; 2012 Nov; 84(4):968-72. PubMed ID: 22898380
[TBL] [Abstract][Full Text] [Related]
17. Moderately hypofractionated carbon ion radiotherapy for prostate cancer; a prospective observational study "GUNMA0702".
Kawamura H; Kubo N; Sato H; Mizukami T; Katoh H; Ishikawa H; Ohno T; Matsui H; Ito K; Suzuki K; Nakano T;
BMC Cancer; 2020 Jan; 20(1):75. PubMed ID: 32000716
[TBL] [Abstract][Full Text] [Related]
18. Anterior-oriented proton beams for prostate cancer: A multi-institutional experience.
Cuaron JJ; Harris AA; Chon B; Tsai H; Larson G; Hartsell WF; Hug E; Cahlon O
Acta Oncol; 2015 Jun; 54(6):868-74. PubMed ID: 25591937
[TBL] [Abstract][Full Text] [Related]
19. Hypofractionated intensity-modulated radiotherapy (70 gy at 2.5 Gy per fraction) for localized prostate cancer: long-term outcomes.
Kupelian PA; Thakkar VV; Khuntia D; Reddy CA; Klein EA; Mahadevan A
Int J Radiat Oncol Biol Phys; 2005 Dec; 63(5):1463-8. PubMed ID: 16169683
[TBL] [Abstract][Full Text] [Related]
20. Evidence for efficacy without increased toxicity of hypofractionated radiotherapy for prostate carcinoma: early results of a Phase III randomized trial.
Yeoh EE; Fraser RJ; McGowan RE; Botten RJ; Di Matteo AC; Roos DE; Penniment MG; Borg MF
Int J Radiat Oncol Biol Phys; 2003 Mar; 55(4):943-55. PubMed ID: 12605972
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
